Citiscan

Quick links to important sections

Citiscan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citiscan

Quick Facts

Property Description
Active ingredient Citicoline (Cytidine Diphosphate-Choline)
Form Oral solution, Tablets/Capsules, Solution for Injection
Pharmacological class Nootropic Agent, Neuroprotector
Typical use scenario Support for cognitive health and neuronal recovery
Origin Synthetic compound

What is Citiscan and its Pharmacological Class?

Citiscan is a pharmaceutical preparation containing the active ingredient Citicoline, which is the International Nonproprietary Name (INN) for Cytidine Diphosphate-Choline (CDP-Choline). This medicine is classified within the World Health Organization's Anatomical Therapeutic Chemical (ATC) system as a nootropic agent and a neuroprotector. The substance is chemically synthesized, ensuring high purity, and is a single-ingredient compound. This classification confirms the drug's specialized role in influencing and supporting the functional and structural health of the central nervous system.

Citiscan: Available Forms and General Purpose

The Citiscan preparation is notable for its availability across multiple pharmaceutical preparations, including oral solutions, tablets, capsules, and a solution for injection (ampoules). This range of delivery systems, encompassing both oral and parenteral routes, allows for flexibility in clinical use. The medicine's primary general purpose is to offer neuroprotection and general cognitive support for adult patient groups. Pharmacological studies have repeatedly shown that Citicoline possesses neuroprotective properties which supports its broad use in maintaining brain function and resilience.

Citiscan's Role in Supporting Neuronal Health

Citicoline's defining function is its ability to serve as a crucial precursor for the biosynthesis of Phosphatidylcholine, the primary phospholipid required for the integrity and repair of neuronal cell membranes. By supplying this essential building block, the compound helps stabilize cell structures and promotes effective neurotransmission. This mechanism is clinically recognized for supporting memory and attention indicating its value lies in bolstering the fundamental physiological health of the central nervous system.

What side effects are possible with Citiscan?

Possible Side Effects and Safety Information

The safety profile of Citiscan, which contains Citicoline, is defined by information documented in official government regulatory labels. Most adverse reactions are classified as occurring Very Rarely (lt 1/10,000 patients treated), including isolated single cases, according to regulatory standards.

Adverse reactions are officially grouped by System-Organ Classes (SOC) and may include effects on the Nervous System (e.g., headache, dizziness, insomnia), Gastrointestinal System (e.g., nausea, vomiting, gastric pain), and Cardiac System (e.g., transient blood pressure changes, tachycardia, bradycardia). Effects on Skin and Subcutaneous Tissue (e.g., rash, urticaria) and General Disorders (e.g., malaise, fever sensation) are also documented.

Specific formulations may contain excipients, such as Sodium Metabisulfite, which is noted in regulatory warnings for its potential to cause serious allergic-type reactions, including anaphylactic symptoms or asthmatic episodes.

Safety Restrictions and Special Populations

Use of the medicine is contraindicated in patients with known hypersensitivity to any component and in individuals with hypertonia of the parasympathetic nervous system.

For pregnant or lactating women and children, use is generally restricted to situations where the expected benefit is determined to outweigh the potential risk, due to limited clinical experience. No specific dosage adjustment is required for older adults. Regulatory safety notes also specify that intravenous administration must be conducted very slowly to prevent episodes of transient hypotension.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Citiscan (Citicoline) overdose is defined by the medicine’s low toxicological risk in humans. Regulatory authorities classify the drug as having a very low toxicity profile in humans. This profile indicates that the appearance of acute intoxication is generally considered unlikely, even if therapeutic dosage levels are accidentally exceeded.

Documented Manifestations and Risk

Entity Official Regulatory Statement
Documented overdose presentations Very low toxicity profile in humans. Observed to be safe at doses up to 2 g/day in clinical use.
Serious / life-threatening outcomes None explicitly documented as a result of acute overdose. Pre-clinical data indicate no lethal dose was determined as no deaths occurred at the maximum possible oral dose administered.
Antidote information No specific antidote is mentioned in the regulatory documents for the management of Citicoline overdose.

Emergency Actions Required

Regulatory instructions mandate professional assessment for any suspected overexposure scenario.

Entity Official Regulatory Statement
When immediate medical help is required Seek emergency medical treatment or contact a doctor in case of overdose.
Supportive management Management of accidental overdose requires that symptomatic therapy is carried out to address any resulting clinical signs.

This structure confirms that the official overdose protocol focuses on ensuring proper medical assessment. This requires individuals to seek medical help immediately upon suspicion of overdose to allow for clinical evaluation and appropriate supportive treatment.

Therapeutic Uses of Citiscan

What Citiscan Treats: Main Uses and Benefits

Citiscan is applied in clinical settings that involve acute or unstable symptom patterns linked to cerebral events, specifically following an acute ischemic stroke or traumatic brain injury (TBI). The use of this medicine is considered relevant across domains involving general cerebrovascular disorders and the management of motor and cognitive symptoms associated with Parkinsonism. Its use helps address groups of symptoms that may appear suddenly and provides support that helps ease the overall symptom burden during a neurological crisis.

Quick Fact: Support for Cognitive Symptom Management Citiscan is relevant in conditions characterized by periods of heightened symptoms related to progressive cognitive impairment, such as vascular dementia and age-related memory loss. It is applied in addressing pronounced symptoms of memory loss, attention deficits, and impaired executive functions that create noticeable physiological strain.

The support offered may assist the patient during difficult episodes and assists with maintaining functional stability when symptoms interfere with routine activities. The medicine is also considered relevant in conditions presenting with systemic or localized discomfort related to neurological disorders and non-cognitive sequelae like disorientation, dizziness, and severe lack of initiative. This usage is applied in addressing symptoms that interfere with daily functioning.

Regulatory References

  1. Philippines FDA summary of Citicoline indications

Eligibility and Restrictions for Use

Eligibility for Citiscan: Official Regulatory Information

Citiscan use is strictly governed by regulatory documentation defining who is permitted to use the medicine, who is restricted, and who is prohibited.

Category Official Regulatory Status
Established User Group Adult Patients are the population for whom Citiscan is generally approved and established for use under standard conditions.
Absolute Contraindications Use is prohibited for patients with a known hypersensitivity to Citicoline or any component of the formulation. It is also contraindicated in patients with hypertonia of the parasympathetic nervous system.
Pediatric Use (Children/Infants) Use is not recommended because regulatory bodies report no data on safety and effectiveness is established for this population.
Pregnancy and Lactation Use is permitted only if the potential benefits justify the potential risks, as there is not enough evidence on safety for pregnant or breastfeeding women.

Eligibility-related restrictions also apply to specific clinical conditions. Patients with persistent intracranial hemorrhage must receive administration under conditional protocols, often requiring very slow infusion rates for intravenous forms. These official classifications determine the precise boundaries for Citiscan's use, focusing on population-specific risks and the completeness of regulatory data.

What should I know about interactions with other medicines?

Citiscan Interactions with other medicines and products

This section describes the officially documented interaction patterns between Citiscan (Citicoline) and other substances, based solely on information found in authoritative government regulatory documents and drug labels. The interaction profile is defined by two specific drug-drug relationships.

Interacting Substance Interaction Classification Official Regulatory Statement
Meclofenoxate (Clophenoxate) Contraindicated Combination Co-administration is formally prohibited. The medicine must not be administered concurrently with medicaments containing Meclofenoxate due to regulatory interaction restrictions.
Levodopa (L-dopa) Pharmacodynamic Potentiation Citicoline is documented to potentiate the effects of Levodopa. This is an official pharmacodynamic interaction resulting in an alteration of the co-administered drug's action.

Other Interaction Information

The regulatory interaction profile for Citiscan does not include formally documented data concerning several key categories. No specific interaction is officially stated regarding drug-metabolizing CYP enzymes or drug transporters. Furthermore, there are no documented mandatory timing or separation rules for administration beyond the Meclofenoxate prohibition. The official labels also do not specify interactions with common elements such as food, alcohol, or herbal products. This profile confirms the specific constraints established by regulatory health authorities.

Mechanism of Action

Citiscan is a non-pharmacological imaging process that utilizes a rotational X-ray source and detector array to acquire data on tissue-specific attenuation of ionizing radiation. The X-ray photons interact with biological tissues, leading to photo-electric absorption and Compton scattering, where the degree of attenuation is directly proportional to the physical density and atomic number of the targeted tissue.

Photons traverse the subject, and the residual beam intensity is measured by detectors. The resulting attenuation profiles from multiple angular projections are transmitted as electronic signals to a computational system. This system then applies a tomographic reconstruction algorithm, such as filtered back-projection or iterative reconstruction, to solve the inverse problem and generate a matrix of linear attenuation coefficients, quantified in Hounsfield units (HU). This cross-sectional dataset constitutes the system-level physiological modulation by providing differentiated visualization of internal anatomical structures based on their distinct radiodensities.

Dosage and Administration Information

How to Use Citiscan

This section outlines the standardized usage of Citiscan (Citicoline), focusing strictly on administration principles and dosage structure.


Administration Scope

Feature Instruction
Route of Administration Approved for both oral intake (as tablets, capsules, or solution) and parenteral delivery via intramuscular (IM) or intravenous (IV) injection.
Standard Adult Dose The standard daily dosing range for adults is 500 mg to 2000 mg of Citicoline per day.
Dosing Frequency The total daily dose may be taken once daily or via divided use (e.g., twice daily).
Timing Relative to Food The oral formulation can be taken with or without food.

Procedural and Population Rules

Age-Group Administration: Dosage adjustments for older adults are typically not required based on age; however, dose modifications may be necessary for any patient presenting with diminished renal function. The safety and effectiveness of the medicine have not been established in children.

Special Procedural Conditions: When administered intravenously, the solution must be delivered slowly over a period of at least three to five minutes. For specific acute conditions, a very slow intravenous infusion rate may be required. Oral tablets must be swallowed whole.

Missed Dose Protocol: If a scheduled dose is missed, the protocol is to take only the next scheduled dose as planned and to not take a double dose to compensate.

This instruction set defines the procedural structure for administering Citiscan, ensuring delivery follows established patterns regarding dose, frequency, and method of intake.

Recent Clinical Evidence

Citiscan: Recent Clinical Evidence

Overview of Clinical Research

Studies have explored the potential effects of the compound Citiscan. Research examined whether the compound could influence self-reported quality of life measures. Research investigated the compound's profile across different age groups in clinical trials.

Studies evaluated whether the compound was associated with a reduction in pain scores and changes in the time to symptom-relief onset. Research findings reported a measured change in disease activity over a 12-month period. Research has also focused on the compound's effect on biological pathways that influence inflammation. Studies have examined the potential for therapeutic effects.

Comparative Studies

A comparison study investigated the outcomes of combination treatment (Citiscan plus standard therapy) versus monotherapy (standard therapy alone).

Research assessed if the combination was correlated with changes in long-term outcomes. Some research has explored the therapeutic profile of the new regimen. Findings from these studies have been published in peer-reviewed journals.

Important Considerations for Patients

It is not yet clear whether the compound is appropriate for all patients or conditions. Research is ongoing to better understand its full range of effects and suitability in various clinical scenarios.

Frequently Asked Questions (FAQ)

Common questions about Citiscan (FAQ)


Q: Does Citiscan interact with common pain relievers like ibuprofen?

Official regulatory documents and product labels only list specific interactions with the medicines Meclofenoxate and Levodopa. The labels do not formally specify interactions with common over-the-counter pain relievers such as ibuprofen.


Q: Are there known interactions between Citiscan and alcohol?

According to the official product information, there is generally no specific interaction stated between the active ingredient in Citiscan and alcohol. Regulatory sources advise patients to follow all directions provided in the official product documentation.


Q: Is the effectiveness of Citiscan proven by high-level evidence?

Research has investigated potential effects of Citiscan in clinical trials, with some studies indicating a measured change in outcomes. However, official documents often note that it is not yet clear whether the compound is appropriate for all specific conditions.


Q: What is the difference between Citiscan and a placebo in clinical trials?

Clinical research has examined Citiscan in comparison with a placebo (an inactive substance) as well as against standard therapy alone. These comparative studies report that Citiscan was associated with a measured change in disease activity and other specified metrics over the trial period.


Q: How is Citiscan eliminated from the body?

The active ingredient in Citiscan, Citicoline, is broken down into its basic components within the body. Official pharmacokinetic studies indicate that the main pathways for elimination are via respiratory carbon dioxide and urinary excretion.


Q: Can Citiscan be crushed or split?

Regulatory guidance for the use of Citiscan explicitly instructs that the oral tablet form must be swallowed whole. This statement defines the standard administration protocol for the tablet form as stated in official labeling.


Q: Is Citiscan the same type of medicine as [similar-sounding drug name]?

Citiscan contains the active ingredient Citicoline, which is classified as a nootropic agent and neuroprotector. This classification refers to its role in influencing and supporting the health of the central nervous system, distinguishing it from other types of medicines.


Q: How quickly should I expect Citiscan to start working?

Official pharmacokinetic studies indicate that the active ingredient is rapidly absorbed after taking an oral dose. Plasma levels have been observed to peak in two stages: initially around 1 hour after administration and again at approximately 24 hours post-dosing.


Q: Can Citiscan be taken by people with kidney issues?

Official product information does not list kidney issues as a direct contraindication for Citiscan. However, regulatory documents mention that official prescribing information includes guidance for use in patients presenting with diminished renal function (impaired kidney function).


Q: Is it okay to drive or operate machinery while using Citiscan?

Regulatory documents list central nervous system effects such as dizziness and headache as possible, though very rare, side effects. Due to the possibility of these very rare effects, the official documentation suggests that caution is appropriate when performing activities that require mental alertness, such as driving or operating machinery.


Q: What kind of studies have been done on Citiscan?

Studies cited in official regulatory sources have explored the compound’s effects on self-reported quality of life measures, its profile across different age groups, and included comparative studies against standard therapy alone in clinical settings.


Q: Is Citiscan considered a long-term treatment or just for short periods?

Official prescribing information does not define a mandatory treatment length. However, the use of the active ingredient has been examined in clinical studies for periods up to 12 months or longer.


Q: Can people with a history of heart problems use Citiscan?

The safety profile does not list a history of heart problems as a contraindication. However, regulatory documents report that side effects can include transient changes in blood pressure (hypotension) and heart rate (tachycardia or bradycardia).


Q: What are the most commonly reported side effects of Citiscan?

Most adverse reactions reported in official regulatory documents are classified as occurring Very Rarely (less than 1 in 10,000 patients). The documented effects include gastrointestinal issues (e.g., nausea, vomiting, stomach pain), nervous system effects (headache, dizziness), and transient blood pressure changes.


Q: Does Citiscan cause changes in mood or sleep?

Regulatory documents list insomnia (difficulty sleeping) as a possible side effect related to the nervous system. There is no explicit mention in the safety profile about Citiscan causing broader changes in mood.


Q: Is Citiscan a controlled substance?

No, the active ingredient in Citiscan, Citicoline, is not classified as a controlled substance under the US Controlled Substances Act or comparable international drug scheduling lists.


Q: Why does Citiscan have different dosages for different people?

Official prescribing information is structured around a standard daily dosing range (e.g., 500 mg to 2000 mg). This range exists because the total daily dose may be adjusted by a healthcare professional and can be taken once daily or via divided use.


Q: Can I take Citiscan if I have a stomach ulcer?

The official safety profile reports that adverse drug reactions can involve the gastrointestinal system, including symptoms like stomach pain and epigastric distress. A pre-existing stomach ulcer is not listed as a contraindication.


Q: Are there different brand names for the same medicine as Citiscan?

Yes. Citiscan's active ingredient, Citicoline, is the International Nonproprietary Name (INN), meaning the same compound is available globally under various different brand names.


Q: Do I need a special diet while taking Citiscan?

No special dietary restrictions are specified in the official regulatory documents. The oral formulation of Citiscan can typically be taken with or without food.


Q: Is it normal to feel tired when starting Citiscan?

Yes, official regulatory documents list fatigue as a possible nervous system side effect, though it is reported to occur very rarely.


Q: What are the signs of a serious side effect from Citiscan?

Serious reactions associated with certain excipients (inactive ingredients) in some formulations have been documented, including severe allergic-type responses such as anaphylactic symptoms or serious asthmatic episodes.


Q: Why is Citiscan only available by prescription?

In many jurisdictions, the active ingredient in Citiscan is regulated as a prescription medicine. This categorization is typically based on its specific indications, the need for professional diagnosis, and the importance of clinical monitoring.


Q: Is Citiscan an antibiotic?

No, Citiscan is not an antibiotic. It is officially classified within the healthcare system as a nootropic agent and a neuroprotector, meaning its function relates to supporting the nervous system.


Q: Does Citiscan have a generic version available?

Yes. Citiscan contains Citicoline, which is the International Nonproprietary Name (INN). This name is used for the generic version of the active compound worldwide.


Q: What does the patient leaflet say about overdose of Citiscan?

Official documents state that the active ingredient has a very low toxicity profile in humans. It has been observed to be generally well-tolerated at doses significantly higher than the typical daily therapeutic range.


Q: Can Citiscan be taken with vitamins or minerals?

Official regulatory labels only list interactions with specific prescription drugs (Meclofenoxate and Levodopa). The documents do not specify any formal interactions with common over-the-counter vitamins or minerals.


Q: Is Citiscan safe for people with high blood pressure?

The safety profile does document that transient hypotension (temporary low blood pressure) can occur as a side effect, particularly if the injectable form is administered too quickly. No general contraindication is listed for pre-existing high blood pressure.


Q: What is the role of Citiscan in managing [specific symptom related to its use]?

The medicine's general purpose is to offer neuroprotection and general cognitive support to adult patient groups. It is clinically recognized for supporting mental functions like memory and attention.


Q: Is Citiscan used to prevent a condition or treat one that already exists?

The compound is clinically recognized for bolstering the fundamental physiological health of the central nervous system. This role includes supporting neuronal health and recovery, suggesting its use in both supportive and treatment contexts.


How should Citiscan be stored and disposed of?

How to Store and Dispose of Citiscan

Official regulatory documents mandate strict conditions for storing and disposing of Citiscan (Citicoline) preparations to maintain stability and ensure safety.

Storage Requirements

  • Temperature and Environment: The medicine must be stored at a temperature below 30°C in a cool and dry place, protected from light. The oral solution form is specifically instructed not to freeze.
  • Child Safety: All forms of the product must be kept out of the sight and reach of children.
  • Stability: The solution for injection is strictly for single use only and must be administered immediately after opening the ampoule.

Disposal Instructions

  • Prohibited Disposal: Unused or expired Citiscan must not be thrown away in wastewater or general household waste.
  • Regulatory Compliance: Patients are instructed to consult a pharmacist for guidance on how to properly dispose of the medicine in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citiscan found in:

A-Z Index: